211 related articles for article (PubMed ID: 24760112)
1. Clinical trials of intravenous immunoglobulin for Alzheimer's disease.
Relkin N
J Clin Immunol; 2014 Jul; 34 Suppl 1():S74-9. PubMed ID: 24760112
[TBL] [Abstract][Full Text] [Related]
2. Intravenous immunoglobulins for Alzheimer's disease.
Puli L; Tanila H; Relkin N
Curr Alzheimer Res; 2014; 11(7):626-36. PubMed ID: 25115546
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulation and AD--down but not out.
Knight EM; Gandy S
J Clin Immunol; 2014 Jul; 34 Suppl 1():S70-3. PubMed ID: 24781637
[TBL] [Abstract][Full Text] [Related]
4. Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence.
Dodel R; Neff F; Noelker C; Pul R; Du Y; Bacher M; Oertel W
Drugs; 2010 Mar; 70(5):513-28. PubMed ID: 20329802
[TBL] [Abstract][Full Text] [Related]
5. Overview of immunotherapy in Alzheimer's disease (AD) and mechanisms of IVIG neuroprotection in preclinical models of AD.
Counts SE; Lahiri DK
Curr Alzheimer Res; 2014; 11(7):623-5. PubMed ID: 25156573
[No Abstract] [Full Text] [Related]
6. Naturally occurring autoantibodies against Aβ oligomers exhibited more beneficial effects in the treatment of mouse model of Alzheimer's disease than intravenous immunoglobulin.
Wang T; Xie XX; Ji M; Wang SW; Zha J; Zhou WW; Yu XL; Wei C; Ma S; Xi ZY; Pang GL; Liu RT
Neuropharmacology; 2016 Jun; 105():561-576. PubMed ID: 26907803
[TBL] [Abstract][Full Text] [Related]
7. A phase 3 trial of IV immunoglobulin for Alzheimer disease.
Relkin NR; Thomas RG; Rissman RA; Brewer JB; Rafii MS; van Dyck CH; Jack CR; Sano M; Knopman DS; Raman R; Szabo P; Gelmont DM; Fritsch S; Aisen PS;
Neurology; 2017 May; 88(18):1768-1775. PubMed ID: 28381506
[TBL] [Abstract][Full Text] [Related]
8. Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease.
Magga J; Puli L; Pihlaja R; Kanninen K; Neulamaa S; Malm T; Härtig W; Grosche J; Goldsteins G; Tanila H; Koistinaho J; Koistinaho M
J Neuroinflammation; 2010 Dec; 7():90. PubMed ID: 21138577
[TBL] [Abstract][Full Text] [Related]
9. Aβ levels in the jugular vein and high molecular weight Aβ oligomer levels in CSF can be used as biomarkers to indicate the anti-amyloid effect of IVIg for Alzheimer's disease.
Kasai T; Kondo M; Ishii R; Tanaka A; Ataka S; Shimada H; Tomiyama T; Mori H; Taylor M; Allsop D; Nakagawa M; Mizuno T; Tokuda T
PLoS One; 2017; 12(4):e0174630. PubMed ID: 28394917
[TBL] [Abstract][Full Text] [Related]
10. Intravenous immunoglobulin (IVIG) treatment exerts antioxidant and neuropreservatory effects in preclinical models of Alzheimer's disease.
Counts SE; Ray B; Mufson EJ; Perez SE; He B; Lahiri DK
J Clin Immunol; 2014 Jul; 34 Suppl 1(0 1):S80-5. PubMed ID: 24760109
[TBL] [Abstract][Full Text] [Related]
11. [Immunotherapy for Alzheimer's disease].
Falkentoft AC; Hasselbalch SG
Ugeskr Laeger; 2016 Jan; 178(3):V07150588. PubMed ID: 26815584
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for Alzheimer's disease.
Steinitz M
Immunotherapy; 2009 May; 1(3):461-9. PubMed ID: 20635962
[TBL] [Abstract][Full Text] [Related]
13. Developing novel immunogens for a safe and effective Alzheimer's disease vaccine.
Lemere CA
Prog Brain Res; 2009; 175():83-93. PubMed ID: 19660650
[TBL] [Abstract][Full Text] [Related]
14. Comparison of ELISA measurements of anti-Aβ concentrations and percentages of specific binding to Aβ between unfractionated intravenous immunoglobulin products and their purified anti-Aβ antibodies.
Klaver AC; Coffey MP; Smith LM; Loeffler DA
Immunol Lett; 2013; 154(1-2):7-11. PubMed ID: 23928186
[TBL] [Abstract][Full Text] [Related]
15. ELISA measurement of specific antibodies to phosphorylated tau in intravenous immunoglobulin products.
Loeffler DA; Klaver AC; Coffey MP
Int Immunopharmacol; 2015 Oct; 28(2):1108-12. PubMed ID: 26330100
[TBL] [Abstract][Full Text] [Related]
16. Naturally occurring autoantibodies against β-Amyloid.
Bach JP; Dodel R
Adv Exp Med Biol; 2012; 750():91-9. PubMed ID: 22903668
[TBL] [Abstract][Full Text] [Related]
17. Antibody Assay and Anti-Inflammatory Function Evaluation of Therapeutic Potential of Different Intravenous Immunoglobulins for Alzheimer's Disease.
Fei Z; Pei R; Pan B; Ye S; Zhang R; Ma L; Wang Z; Li C; Du X; Cao H
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982622
[TBL] [Abstract][Full Text] [Related]
18. Intravenous immunoglobulin and Alzheimer's disease immunotherapy.
Solomon B
Curr Opin Mol Ther; 2007 Feb; 9(1):79-85. PubMed ID: 17330405
[TBL] [Abstract][Full Text] [Related]
19. Should development of Alzheimer's disease-specific intravenous immunoglobulin be considered?
Loeffler DA
J Neuroinflammation; 2014 Dec; 11():198. PubMed ID: 25476011
[TBL] [Abstract][Full Text] [Related]
20. Aβ anti-idiotypic antibodies are present in intravenous immunoglobulin and are produced in mice following its administration.
Loeffler DA; Klaver AC; Coffey MP
Autoimmunity; 2015 Jun; 48(4):196-200. PubMed ID: 25392130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
